Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaIoana Agache, Marek Jutel, Thomas B. Casale et al.|Allergy|2020Cited by 406
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaIoana Agache, Marek Jutel, Claudio Rocha et al.|Allergy|2020Cited by 139
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthmaIoana Agache, Marek Jutel, Yang Song et al.|Allergy|2020Cited by 89